Bausch Health Companies Inc. splits its revenue into 3 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Product at $2.9 billion, 99% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
11,113
|
2,941
|
2,852
|
2,524
|
2,796
|
2,681
|
2,530
|
2,259
|
2,559
|
| Product |
11,005
+11.0%
share 99.0%
|
2,912
+9.6%
share 99.0%
|
2,825
+12.8%
share 99.1%
|
2,500
+12.3%
share 99.0%
|
2,768
+9.5%
share 99.0%
|
2,657
share 99.1%
|
2,504
share 99.0%
|
2,227
share 98.6%
|
2,528
share 98.8%
|
| Product And Service Other |
108
-4.4%
share 1.0%
|
29
+20.8%
share 1.0%
|
27
+3.8%
share 0.9%
|
24
-25.0%
share 1.0%
|
28
-9.7%
share 1.0%
|
24
share 0.9%
|
26
share 1.0%
|
32
share 1.4%
|
31
share 1.2%
|
| Price Appreciation Credit |
—
|
—
|
—
|
2
+0.0%
share 0.1%
|
15
share 0.5%
|
—
|
—
|
2
share 0.1%
|
—
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BHC (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- NJ
- Headquarters
- Quebec, Quebec, Canada
- SEC filer status
- Large accelerated filer
- SEC CIK
- 885590
- Former names
- Valeant Pharmaceuticals International, Inc. (until Jul 3, 2018); BIOVAIL Corp (until Sep 27, 2010); BIOVAIL CORP INTERNATIONAL (until Apr 7, 2010); BIOVAIL CORPORATION INTERNATIONAL (until Jan 5, 2001)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.